Answer
Clobazam is a weak CYP2D6 inhibitor, and co-administration increased dextromethorphan exposure by 90% for AUC and 59% for peak plasma concentration (Cmax).
Sources for this answer
- Tapclob/Clobazam 10mg/5ml Oral SuspensionMartindale Pharma, an Ethypharm Group Company · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked